United States

FDA approves Eliquis to reduce blood clots non-valvular atrial fibrillation

Wednesday, January 2, 2013 02:48 PM

The FDA has approved Bristol-Myers Squibb and Pfizer’s anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem.

More... »

JHP Pharmaceuticals acquired By Warburg Pincus

Wednesday, January 2, 2013 02:28 PM

JHP Pharmaceuticals, a Parsippany, N.J.-based specialty pharmaceutical focused on sterile injectable products, has been acquired by an affiliate of Warburg Pincus, a leading global private equity firm focused on growth investing, for $195 million on a debt-free, cash-free basis. JHP's current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.

More... »

Texas Health Resources selects Daniel Varga as CCO

Wednesday, December 19, 2012 12:08 PM

Texas Health Resources, a faith-based, nonprofit health system, has selected Daniel Varga, M.D., as its chief clinical officer (CCO) and senior executive vice president of the health system, effective Jan. 14.

More... »

Regado Biosciences secures $51M Series E financing

Wednesday, December 19, 2012 10:13 AM

Regado Biosciences, a Basking Ridge, N.J.-based private biopharmaceutical company developing antithrombotic aptamers with active control agents, has secured a landmark $51 million Series E financing. 

More... »

Zuckerman gives $200M to Columbia University, endows Mind Brain Behavior Institute

Tuesday, December 18, 2012 12:29 PM

Mortimer B. Zuckerman has pledged $200 million to endow a Mind Brain Behavior Institute at Columbia University to support interdisciplinary neuroscience research and discovery by scholars across the university.

More... »

FDA clears IND for first study protocol developed using crowdsourcing

Tuesday, December 18, 2012 12:02 PM

The FDA has cleared the Investigational New Drug Application (IND) for lisinopril to be assessed as an adjunctive therapy for multiple sclerosis (MS), according to Transparency Life Sciences (TLS), a drug development company based on open innovation.

More... »

UAB to enroll patients in pilot study using Mytrus’ iPad app

Tuesday, December 18, 2012 11:08 AM

The University of Alabama at Birmingham (UAB) will use an iPad application developed by Mytrus, a clinical technology and services company for medical and pharmaceutical research, in an upcoming pilot study supported by the U.S. Department of Health & Human Services Agency for Healthcare Research and Quality.  

More... »

Takeda sells non-Colcrys URL Pharma to Sun Pharmaceutical

Tuesday, December 18, 2012 10:13 AM

Takeda Pharmaceuticals U.S.A. has entered into a definitive agreement to sell the non-Colcrys (colchicine, USP) URL Pharma generic business to Caraco Pharmaceutical Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries.

More... »

Soligenix acquires novel innate defense regulator clinical program

Tuesday, December 18, 2012 09:44 AM

Soligenix, a Princeton, N.J.-based development stage biopharmaceutical company, has acquired a novel drug technology, known as SGX94, representing a unique approach to modulation of the innate immune system. 

More... »

FDA approves GSK's four-strain seasonal influenza vaccine

Monday, December 17, 2012 04:28 PM

The FDA has approved GlaxoSmithKline’s Fluarix Quadrivalent (influenza virus vaccine) for the immunization of adults and children (three years and older) to help prevent disease caused by seasonal influenza virus subtypes A and B contained in the vaccine.

More... »